Repligen Co. (NASDAQ:RGEN) Holdings Boosted by Lindenwold Advisors

Lindenwold Advisors boosted its holdings in Repligen Co. (NASDAQ:RGEN – Get Rating) by 23.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,109 shares of the biotechnology company’s stock after acquiring an additional 210 shares during the period. Lindenwold Advisors’ holdings in Repligen were worth $209,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. HM Payson & Co. acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $26,000. Confluence Wealth Services Inc. acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $27,000. Sageworth Trust Co of South Dakota acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $46,000. Tobam increased its stake in shares of Repligen by 47.7% in the first quarter. Tobam now owns 260 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 84 shares during the period. Finally, Rise Advisors LLC acquired a new position in shares of Repligen during the fourth quarter valued at approximately $52,000. Institutional investors own 86.82% of the company’s stock.

Repligen Stock Performance

Repligen stock opened at $246.27 on Friday. The firm has a market cap of $13.67 billion, a price-to-earnings ratio of 88.91, a price-to-earnings-growth ratio of 10.93 and a beta of 1.07. Repligen Co. has a 1 year low of $137.21 and a 1 year high of $327.32. The firm’s 50 day moving average price is $175.20 and its two-hundred day moving average price is $174.08.

Repligen (NASDAQ:RGEN – Get Rating) last posted its quarterly earnings data on Tuesday, August 2nd. The biotechnology company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.19. Repligen had a net margin of 20.47% and a return on equity of 11.18%. The firm had revenue of $207.63 million during the quarter, compared to analyst estimates of $189.06 million. During the same quarter last year, the business posted $0.79 EPS. The company’s revenue was up 27.4% on a year-over-year basis. As a group, equities analysts predict that Repligen Co. will post 3.18 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Christine Gebski sold 3,357 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $243.01, for a total value of $815,784.57. Following the completion of the transaction, the insider now owns 30,735 shares of the company’s stock, valued at approximately $7,468,912.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Repligen news, COO James Bylund sold 2,000 shares of Repligen stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $240.40, for a total transaction of $480,800.00. Following the completion of the sale, the chief operating officer now owns 9,733 shares of the company’s stock, valued at approximately $2,339,813.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Christine Gebski sold 3,357 shares of Repligen stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $243.01, for a total transaction of $815,784.57. Following the sale, the insider now directly owns 30,735 shares of the company’s stock, valued at approximately $7,468,912.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,874 shares of company stock valued at $8,911,739. Company insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on RGEN. SVB Leerink raised their price objective on shares of Repligen from $220.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday. KeyCorp raised their price objective on shares of Repligen from $245.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday. UBS Group began coverage on shares of Repligen in a research note on Wednesday, July 20th. They set a “buy” rating and a $213.00 price objective on the stock. Craig Hallum lowered their price objective on shares of Repligen from $286.00 to $274.00 in a research note on Thursday, April 28th. Finally, Stephens raised their price objective on shares of Repligen from $220.00 to $275.00 and gave the company an “overweight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $276.00.

Repligen Profile

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.